Capastat Sulfate — Competitive Intelligence Brief

Capastat Sulfate (CAPREOMYCIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimycobacterial. Area: Infectious Disease.

marketed Antimycobacterial Infectious Disease Recombinant protein

Target snapshot

Capastat Sulfate (CAPREOMYCIN) — Epic Pharma Llc.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Capastat Sulfate TARGET	CAPREOMYCIN	Epic Pharma Llc	marketed	Antimycobacterial		1971-01-01
Sirturo	bedaquiline	Janssen Therap	marketed	Diarylquinoline Antimycobacterial	Potassium voltage-gated channel subfamily H member 2	2012-01-01
Priftin	RIFAPENTINE	Sanofi	marketed	Rifamycin Antimycobacterial [EPC]		1998-01-01
Lamprene	clofazimine	Novartis	marketed	Antimycobacterial	ATP-binding cassette sub-family G member 2	1986-01-01
Pyrazinamide	PYRAZINAMIDE	Dava Pharms Inc	marketed	Antimycobacterial [EPC]	Cytochrome P450 3A4	1971-01-01
Myambutol	ETHAMBUTOL	Kanchan Hlthcare	marketed	Antimycobacterial	Cytochrome P450 3A4	1967-01-01
Trecator	ETHIONAMIDE	Pfizer	marketed	Antimycobacterial		1965-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimycobacterial class)

1. Epic Pharma Llc · 1 drug in this class
2. Kanchan Hlthcare · 1 drug in this class
3. Novartis · 1 drug in this class
4. Pfizer · 1 drug in this class